Ascendis Pharma AS
ASND
Company Profile
Business description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Contact
Tuborg Boulevard 12
Hellerup2900
DNKT: +45 70222244
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,189
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.20 | 19.30 | 0.22% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,281.32 | 284.58 | -1.16% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 64,681.39 | 735.24 | -1.12% |
| NZX 50 Index | 13,183.81 | 20.27 | -0.15% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,623.30 | 31.90 | 0.37% |
| SSE Composite Index | 3,979.09 | 30.94 | -0.77% |